e-learning
resources
Paris 2018
Monday, 17.09.2018
Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prevalence of progressive fibrosing interstitial lung disease
A. Olson (Denver, Colorado, United States of America), N. Hartmann (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ingelheim am Rhein, Germany), L. Wallace (Ridgefield, Connecticut, United States of America)
Source:
International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Session:
Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Session type:
Thematic Poster
Number:
3030
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Olson (Denver, Colorado, United States of America), N. Hartmann (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ingelheim am Rhein, Germany), L. Wallace (Ridgefield, Connecticut, United States of America). Prevalence of progressive fibrosing interstitial lung disease. 3030
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases.
Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis
Year: 2020
The natural history of progressive fibrosing interstitial lung diseases
Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020
Year: 2020
Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019
Year: 2019
Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD)
Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis
Year: 2021
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Nitrofurantoin-induced interstitial lung disease
Source: Annual Congress 2012 - Viral infections and rare respiratory infections
Year: 2012
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019
Year: 2019
Variation in mortality from interstitial lung disease by diagnosis
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?
Source: Eur Respir J 2011; 38: 384-391
Year: 2011
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018
Year: 2018
Genetics of fibrosing lung diseases
Source: Eur Respir J 2005; 25: 915-927
Year: 2005
Diffuse interstitial pneumonia and pulmonary hypertension: a novel manifestation of chronic granulomatous disease
Source: Eur Respir J 2009; 33: 1498-1502
Year: 2009
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Source: Eur Respir Rev 2012 21: 355-361
Year: 2012
Aquoaporin-1 expression in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease
Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018
Year: 2018
Idiopathic interstitial pneumonia and connective tissue disorder-related interstitial lung disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=170
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept